Massivemarkets

BBIO

BridgeBio Pharma, Inc. Common Stock

Nasdaq · usd

$78.01+1.21 (+1.58%)
As of 4:09:19 AM EST on Nov 19, 2026 · 15-minute delayed

BridgeBio Pharma, Inc. Common Stock (BBIO) trades at $78.01 (+1.58%) as of 4:09:19 AM EST on Nov 19, 2026, +15.48% over the past month. Market cap is $15.2B, with 7.1 days to cover in short interest.

Stock performance

How BridgeBio Pharma, Inc. Common Stock (BBIO) stock has performed from one day to one year, with its 52-week range.

+0.66%
+$0.51 over 1D
$76.15$76.80$77.44$78.097:00 AM11:00 AM12:45 PM2:25 PM8:00 PM$78.01
1D
+1.58%
1W
-1.92%
1M
+15.48%
YTD
+1.99%
1Y
+20.72%
52-wk range
$62.50 – $93.42

Key statistics

Today's trading snapshot for BBIO: day range, open, previous close, volume and market cap.

Day range
$75.99 – $78.25
Open
$76.45
Prev close
$76.80
Volume
3.65M
Market cap
$15.2B
Shares out
194.8M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for BridgeBio Pharma, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
16.07
P/B
-9.14
P/FCF
—
ROE
35.6%
ROA
-27.4%
Debt/Equity
-1.49
Div yield
0.02%

As of Nov 18, 2026

8-K filings

Material corporate events BridgeBio Pharma, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Quarterly earningsOct 29, 2026

    On October 29, 2026, BridgeBio Pharma, Inc. (the "Company") reported recent business updates and its financial results for the third quarter ended September 30, 2026.

  • On October 6, 2026, BridgeBio Pharma, Inc. issued a press release titled "BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia."

  • Public offeringAug 17, 2026

    The Offering was made pursuant to the Company's effective shelf registration statement on Form S-3ASR (File No. 333-297701), including the prospectus dated July 24, 2026, as supplemented by a prospectus supplement dated August 13, 2026, filed on August 14, 2026. The sale of the Shares is expected to be completed on August 17, 2026.

  • BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1. On July 22, 2026, BridgeBio Pharma, Inc. issued a press release titled 'BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1.'

  • Charter amendmentJul 2, 2026

    In connection with the issuance of the Preferred Stock, on the Closing Date, the Company filed a Certificate of Designations with the Secretary of State of the State of Delaware, establishing the designations, powers, preferences and rights of the Preferred Stock. The Certificate of Designations became effective upon filing.

BBIO short interest

How heavily BBIO is shorted: shares short, days to cover and average daily volume.

Days to cover
7.1
Short interest
20.85M
Avg volume
2.95M

As of · reported to FINRA twice monthly.

BBIO news

The latest news and headlines about BridgeBio Pharma, Inc. Common Stock (BBIO).

Frequently asked questions

What is the BridgeBio Pharma, Inc. Common Stock (BBIO) stock price today?

BridgeBio Pharma, Inc. Common Stock (BBIO) is trading at $78.01 (+1.58% on the day) as of 4:09:19 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is BridgeBio Pharma, Inc. Common Stock?

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene…

What is the short interest in BBIO?

As of Oct 30, 2026, BBIO has 20.85M shares short and 7.1 days to cover.

What exchange is BBIO listed on?

BridgeBio Pharma, Inc. Common Stock (BBIO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of BBIO with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BBIO analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.